Mozavaptan

Mozavaptan

Systematic (IUPAC) name
N-[4-(5-Dimethylamino-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]-2-methylbenzamide
Clinical data
Legal status	℞ (Prescription only)
Routes of administration	Oral
Identifiers
CAS Number	137975-06-5 N
ATC code	None
PubChem	CID 119369
IUPHAR/BPS	2197
ChemSpider	106618 Y
UNII	17OJ42922Y Y
ChEMBL	CHEMBL420762 Y
Chemical data
Formula	C27H29N3O2
Molar mass	427.53 g/mol
SMILES CC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)N3CCCC(C4=CC=CC=C43)N(C)C
InChI InChI=1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31) Y Key:WRNXUQJJCIZICJ-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.

References

• H. Spreitzer (November 20, 2006). "Neue Wirkstoffe - Conivaptan". Österreichische Apothekerzeitung (in German) (24/2006). 
• Prous Science: Molecule of the Month November 2006